Switch theme
Sign up to access all valuation multiples
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
2014
104
LTM Revenue $2.6M
Last FY EBITDA -$88.3M
$48.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Korro Bio has a last 12-month revenue (LTM) of $2.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Korro Bio achieved revenue of $2.3M and an EBITDA of -$88.3M.
Korro Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Korro Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.6M | XXX | $2.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$88.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -3890% | XXX | XXX | XXX |
| EBIT | -$95.0M | XXX | -$91.9M | XXX | XXX | XXX |
| EBIT Margin | -3598% | XXX | -4047% | XXX | XXX | XXX |
| Net Profit | -$89.0M | XXX | -$83.6M | XXX | XXX | XXX |
| Net Margin | -3370% | XXX | -3680% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Korro Bio's stock price is $13.
Korro Bio has current market cap of $118M, and EV of $48.1M.
See Korro Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $48.1M | $118M | XXX | XXX | XXX | XXX | $-9.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Korro Bio has market cap of $118M and EV of $48.1M.
Korro Bio's trades at 21.2x EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Korro Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Korro Bio has a P/E ratio of -1.3x.
See valuation multiples for Korro Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $118M | XXX | $118M | XXX | XXX | XXX |
| EV (current) | $48.1M | XXX | $48.1M | XXX | XXX | XXX |
| EV/Revenue | 18.2x | XXX | 21.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKorro Bio's last 12 month revenue growth is -19%
Korro Bio's revenue per employee in the last FY averaged $22K, while opex per employee averaged $0.9M for the same period.
Korro Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Korro Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Korro Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -19% | XXX | -25% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -3890% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -3909% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $22K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2802% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4147% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Korro Bio acquired XXX companies to date.
Last acquisition by Korro Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Korro Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Korro Bio founded? | Korro Bio was founded in 2014. |
| Where is Korro Bio headquartered? | Korro Bio is headquartered in United States of America. |
| How many employees does Korro Bio have? | As of today, Korro Bio has 104 employees. |
| Who is the CEO of Korro Bio? | Korro Bio's CEO is Dr. Ram Aiyar, M.B.A.,PhD. |
| Is Korro Bio publicy listed? | Yes, Korro Bio is a public company listed on NAS. |
| What is the stock symbol of Korro Bio? | Korro Bio trades under KRRO ticker. |
| When did Korro Bio go public? | Korro Bio went public in 2023. |
| Who are competitors of Korro Bio? | Similar companies to Korro Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Korro Bio? | Korro Bio's current market cap is $118M |
| What is the current revenue of Korro Bio? | Korro Bio's last 12 months revenue is $2.6M. |
| What is the current revenue growth of Korro Bio? | Korro Bio revenue growth (NTM/LTM) is -19%. |
| What is the current EV/Revenue multiple of Korro Bio? | Current revenue multiple of Korro Bio is 18.2x. |
| Is Korro Bio profitable? | Yes, Korro Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
